Online citations, reference lists, and bibliographies.
← Back to Search

Clinical Results With Resovist: A Phase 2 Clinical Trial.

P. Reimer, E. Rummeny, H. Daldrup, T. Balzer, B. Tombach, T. Berns, P. Peters
Published 1995 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
PURPOSE To investigate the superparamagnetic iron oxide (Resovist) designed for contrast material-enhanced magnetic resonance imaging of the liver. MATERIALS AND METHODS A phase 2 trial was performed in 33 patients with no more than five known focal solid liver lesions. Resovist was administered intravenously at doses of 4, 8, and 16 mumol of iron per kilogram of body weight. Postcontrast 1.0-T imaging was started 30 minutes after injection. RESULTS Resovist significantly (P < or = .05) decreased liver signal intensity and increased lesion-to-liver contrast-to-noise ratio (C/N) and the number of detectable liver lesions: fast spin-echo (SE) (echo time, 90 msec) precontrast C/N, 11.7 +/- 7.9 [standard deviation]; postcontrast [8-mumol Fe/Kg] C/N, 29.2 +/- 14.2). The dose of 8 mumol Fe/kg was sufficient for the detection of focal liver lesions, and T2-weighted fast SE with an echo time of 90 msec was the overall best pulse sequence. CONCLUSION Resovist is a safe contrast agent, and a dose of 8 mumol Fe/kg is sufficient to enhance detection of focal liver lesions at T2-weighted fast SE MR imaging.



This paper is referenced by
10.1142/S0219836303000335
Imaging Hepatocellular Carcinoma
Hua Thng Choon (2003)
10.1007/978-94-007-1248-5_17
Magnetic resonance tracking of stem cells with iron oxide particles
E. S. Lee (2011)
10.1016/S1076-6332(96)80560-5
Superparamagnetic agents: physicochemical characteristics and preclinical imaging evaluation.
S. Benderbous (1996)
10.1148/RADIOLOGY.218.1.R01JA2427
Contrast agents for MR imaging of the liver.
R. Semelka (2001)
10.1007/s10554-010-9736-7
Characterization of carotid artery plaques with USPIO-enhanced MRI: assessment of inflammation and vascularity as in vivo imaging biomarkers for plaque vulnerability
S. Metz (2010)
10.1007/s00330-002-1677-7
Preoperative evaluation of malignant liver tumors: comparison of unenhanced and SPIO (Resovist)-enhanced MR imaging with biphasic CTAP and intraoperative US
T. Vogl (2002)
Ferucarbotran-enhanced MR imaging in the diagnosis of focal splenic lesions
S. Salemi (2011)
10.1007/978-3-642-59957-6_10
Contrast Media for Clinical Magnetic Resonance Imaging and Ultrasound
Niendorf Hp (1999)
10.1063/1.3211307
Size analysis of carboxydextran coated superparamagnetic iron oxide particles used as contrast agents of magnetic resonance imaging
D. Chen (2009)
10.7150/thno.49812
Highly sensitive magnetic particle imaging of vulnerable atherosclerotic plaque with active myeloperoxidase-targeted nanoparticles
W. Tong (2020)
10.1002/jmri.21608
Safety of ferucarbotran in MR imaging of the liver: A pre‐ and postexamination questionnaire‐based multicenter investigation
H. Onishi (2009)
10.1016/J.BEJ.2008.07.009
Synthesis, characterization and MRI application of dextran-coated Fe3O4 magnetic nanoparticles
R. Y. Hong (2008)
10.1016/j.biomaterials.2013.08.092
The effect of nonuniform magnetic targeting of intracoronary-delivering mesenchymal stem cells on coronary embolisation.
Zheyong Huang (2013)
10.1002/jmri.22098
Comparison of ferucarbotran‐enhanced fluid‐attenuated inversion‐recovery echo‐planar, T2‐weighted turbo spin‐echo, T2*‐weighted gradient‐echo, and diffusion‐weighted echo‐planar imaging for detection of malignant liver lesions
Y. Fukukura (2010)
10.1080/02841859709172392
Liver imaging
E. Rummeny (1997)
10.1148/RADIOLOGY.210.2.R99FE05459
Hepatic lesion detection: comparison of MR imaging after the administration of superparamagnetic iron oxide with dual-phase CT by using alternative-free response receiver operating characteristic analysis.
J. Ward (1999)
Comparison of Breath-Holding Turbo Spin Echo and Expiratory-Triggered HASTE Sequences for Resovist-Enhanced MR Imaging of Liver Lesions
S. Chan (2004)
10.1007/s002619910035
Detection of hepatocellular carcinoma and its metastases with various pulse sequences using superparamagnetic iron oxide (SHU-555-A)
A. Arbab (2000)
10.1039/c4fd00114a
Prolonging the circulatory retention of SPIONs using dextran sulfate: in vivo tracking achieved by functionalisation with near-infrared dyes.
Maha Abdollah (2014)
10.2214/AJR.166.5.8615254
Detection of focal hepatic lesions with MR imaging: prospective comparison of T2-weighted fast spin-echo with and without fat suppression, T2-weighted breath-hold fast spin-echo, and gadolinium chelate-enhanced 3D gradient-recalled imaging.
P. Soyer (1996)
10.1002/JMRI.1880070109
Contrast agents for MR imaging of the liver
R. N. Low (1997)
10.1002/(SICI)1522-2586(199907)10:1<65::AID-JMRI9>3.0.CO;2-0
Contrast‐enhanced 3D‐MRA of the upper abdomen with a bolus‐injectable SPIO (SH U 555 A)
P. Reimer (1999)
10.2214/AJR.174.4.1740947
Preoperative detection of malignant hepatic tumors: comparison of combined methods of MR imaging with combined methods of CT.
H. Kondo (2000)
10.1063/1.3117512
Size determination of superparamagnetic nanoparticles from magnetization curve
D. Chen (2009)
10.1159/000078477
MRI in the Evaluation of Hepatocellular Nodules: Role of Pulse Sequences and Contrast Agents
T. Ichikawa (2004)
10.1016/S0730-725X(00)00116-8
MRI of liver: a comparison of CNR enhancement using high dose and low dose ferumoxide infusion in patients with colorectal liver metastases.
J. Scott (2000)
10.1148/RADIOLOGY.217.1.R00OC31152
Hepatic lesion detection and characterization: value of nonenhanced MR imaging, superparamagnetic iron oxide-enhanced MR imaging, and spiral CT-ROC analysis.
P. Reimer (2000)
10.1016/j.biomaterials.2009.11.062
Deep magnetic capture of magnetically loaded cells for spatially targeted therapeutics.
Zheyong Huang (2010)
10.1159/000333267
Ultrasonography, Computed Tomography and Magnetic Resonance Imaging of Hepatocellular Carcinoma: Toward Improved Treatment Decisions
T. Murakami (2011)
10.1142/S1793292014500696
DYNAMIC MR IMAGING, BIODISTRIBUTION AND PHARMACOKINETICS OF POLYMER SHELLED MICROBUBBLES CONTAINING SPION
Åsa Barrefelt (2014)
10.1097/00004424-199705000-00005
Superparamagnetic iron oxide enhanced magnetic resonance imaging of rat liver with hepatocellular carcinoma and benign hyperplastic nodule.
T. Ishida (1997)
10.1002/(SICI)1522-2586(200004)11:4<418::AID-JMRI10>3.0.CO;2-W
MR contrast agents in acute experimental cerebral ischemia: Potential adverse impacts on neurologic outcome and infarction size
A. Doerfler (2000)
See more
Semantic Scholar Logo Some data provided by SemanticScholar